Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$13.80
+0.9%
$14.14
$8.02
$15.78
$6.79B1.664.28 million shs5.03 million shs
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$11.92
+2.9%
$9.71
$5.78
$12.35
$1.84B1.491.98 million shs1.65 million shs
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
$12.97
-1.7%
$0.00
$0.09
$83.60
N/A2.211.16 million shs368,222 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$36.63
-1.7%
$38.64
$29.17
$62.40
$6.94B1.161.47 million shs978,549 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+0.80%-7.50%-6.31%+41.61%+5.79%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
+2.94%-2.38%+26.00%+35.45%+40.90%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
-1.74%-13.82%+25.19%+1,296,999,900.00%+1,296,999,900.00%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-1.72%-3.35%-1.51%-10.04%-19.74%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
3.8056 of 5 stars
3.44.00.00.32.31.71.3
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
3.6116 of 5 stars
3.51.00.04.11.92.50.0
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
0.0502 of 5 stars
0.02.00.00.00.60.00.0
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4.467 of 5 stars
4.53.00.04.72.81.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.88
Moderate Buy$16.1717.15% Upside
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
3.00
Buy$17.3345.41% Upside
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
0.00
N/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.00
Buy$68.9188.12% Upside

Current Analyst Ratings Breakdown

Latest OCUL, RGC, ELAN, and RVMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/23/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $18.00
7/17/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/17/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$18.00
7/15/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$65.00
7/2/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $17.00
6/26/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
6/25/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
6/24/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$67.00 ➝ $73.00
6/24/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$57.00
5/29/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.54$2.27 per share6.07$12.33 per share1.12
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$63.72M29.80N/AN/A$2.01 per share5.93
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/AN/A$0.02 per shareN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M589.21N/AN/A$13.47 per share2.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7418.6515.512.668.43%7.54%3.57%8/7/2025 (Estimated)
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$193.51M-$1.15N/AN/AN/A-323.09%-59.92%-41.98%8/5/2025 (Estimated)
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
-$4.30MN/A0.00N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$600.09M-$4.00N/AN/AN/AN/A-37.06%-32.84%8/6/2025 (Estimated)

Latest OCUL, RGC, ELAN, and RVMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.1989N/AN/AN/A$1.19 billionN/A
8/6/2025Q2 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.14N/AN/AN/A$0.50 millionN/A
8/5/2025Q2 2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$0.35N/AN/AN/A$13.12 millionN/A
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/7/2025Q1 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.12-$1.13-$0.01-$1.13N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
N/AN/AN/AN/AN/A
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
0.26
10.22
10.14
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/A
13.46
13.46

Institutional Ownership

CompanyInstitutional Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
59.21%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
0.13%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
230159.30 million155.64 millionOptionable
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
10N/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250186.27 million170.99 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$13.80 +0.12 (+0.88%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$13.80 -0.01 (-0.04%)
As of 08/1/2025 05:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Ocular Therapeutix stock logo

Ocular Therapeutix NASDAQ:OCUL

$11.92 +0.34 (+2.94%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$11.92 -0.01 (-0.04%)
As of 08/1/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Regencell Bioscience stock logo

Regencell Bioscience NASDAQ:RGC

$12.97 -0.23 (-1.74%)
As of 08/1/2025 04:00 PM Eastern

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$36.63 -0.64 (-1.72%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$37.25 +0.62 (+1.69%)
As of 08/1/2025 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.